Joshua Doyle
Papers
1
Total Citations
8
H-Index
1
About
Joshua Doyle is a pioneering researcher in the field of targeted cancer therapeutics, with a primary focus on bladder urothelial carcinoma. His work centers on exploiting tumor acidity as a biomarker for precision drug delivery, particularly through the use of pH Low Insertion Peptides (pHLIPs). In his most cited study, "Targeting bladder urothelial carcinoma with pHLIP-ICG and inhibition of urothelial cancer cell proliferation by pHLIP-amanitin" (2022, 8 citations), Doyle demonstrated how pHLIPs can sense the acidic microenvironment of tumor cells and facilitate the intracellular delivery of both cell-permeable and cell-impermeable cargo molecules. This innovative approach enables the selective targeting of metabolically active cancer cells while sparing healthy tissue. By combining pHLIP technology with imaging agents and cytotoxic drugs like amanitin, Doyle has made significant strides in developing more effective and less toxic treatments for bladder cancer. Though early in his career, his contributions are already shaping the future of pH-responsive drug delivery systems, offering new hope for patients with hard-to-treat malignancies.
Research Focus
Key Achievements
Top Papers
- 1